Orient Pharma Co. Ltd.
Orient Pharma Co., Ltd. engages in the development of new drugs in Taiwan and internationally. It offers cardiovascular drugs, such as Pitator and Tonvasca for lipid suppression, as well as Zulitor, a lipid lowering drug; psychotropic drugs, including Trokendi XR extended, Methydur, and powder and solvent for prolonged-release suspension for injection. The company was founded in 2008 and is based… Read more
Market Cap & Net Worth: Orient Pharma Co. Ltd. (4166)
Orient Pharma Co. Ltd. (TWO:4166) has a market capitalization of $183.27 Million (NT$6.06 Billion) as of March 19, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #22103 globally and #1247 in its home market, demonstrating a 2.46% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Orient Pharma Co. Ltd.'s stock price NT$24.95 by its total outstanding shares 243035089 (243.04 Million).
Orient Pharma Co. Ltd. Market Cap History: 2015 to 2026
Orient Pharma Co. Ltd.'s market capitalization history from 2015 to 2026. Data shows growth from $294.33 Million to $183.27 Million (1.62% CAGR).
Orient Pharma Co. Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Orient Pharma Co. Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.16x
Orient Pharma Co. Ltd.'s market cap is 0.16 times its annual revenue
1.11x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
6.54x
Orient Pharma Co. Ltd.'s market cap is 6.54 times its annual earnings
11.76x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $106.51 Million | $353.54 Million | -$201.03 Million | 0.30x | N/A |
| 2020 | $106.88 Million | $412.01 Million | -$171.38 Million | 0.26x | N/A |
| 2021 | $135.89 Million | $463.34 Million | -$102.65 Million | 0.29x | N/A |
| 2022 | $153.15 Million | $511.86 Million | -$28.76 Million | 0.30x | N/A |
| 2023 | $145.81 Million | $889.91 Million | $22.29 Million | 0.16x | 6.54x |
Competitor Companies of 4166 by Market Capitalization
Companies near Orient Pharma Co. Ltd. in the global market cap rankings as of March 19, 2026.
Key companies related to Orient Pharma Co. Ltd. by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Orient Pharma Co. Ltd. Historical Marketcap From 2015 to 2026
Between 2015 and today, Orient Pharma Co. Ltd.'s market cap moved from $294.33 Million to $ 183.27 Million, with a yearly change of 1.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$183.27 Million | -4.59% |
| 2025 | NT$192.09 Million | -27.16% |
| 2024 | NT$263.70 Million | +80.86% |
| 2023 | NT$145.81 Million | -4.80% |
| 2022 | NT$153.15 Million | +12.70% |
| 2021 | NT$135.89 Million | +27.15% |
| 2020 | NT$106.88 Million | +0.34% |
| 2019 | NT$106.51 Million | -7.53% |
| 2018 | NT$115.18 Million | -13.61% |
| 2017 | NT$133.32 Million | -38.08% |
| 2016 | NT$215.30 Million | -26.85% |
| 2015 | NT$294.33 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Orient Pharma Co. Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $183.27 Million USD |
| MoneyControl | $183.27 Million USD |
| MarketWatch | $183.27 Million USD |
| marketcap.company | $183.27 Million USD |
| Reuters | $183.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.